TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
The Pharma Data
JULY 11, 2021
Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin in Berlin, Germany. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. Markus Magerl, M.D., Inhibition of plasma kallikrein by lanadelumab can increase aPTT in this assay.
52 
Let's personalize your content